Comprehensive clinical follow-up of late effects in childhood cancer survivors shows the need for early and well-timed intervention

J. W. Han1, S. Y. Kwon1, S. C. Won1, Y. J. Shin1, J. H. Ko2 & C. J. Lyu1*

Departments of 1Pediatric Hematology and Oncology and 2Pharmacy, Yonsei University Health System, Seoul, Korea

Received 19 April 2008; first revision 23 July 2008; second revision 22 October 2008; accepted 9 December 2008

Background: Due to recent advances in treatment, nearly 80% of childhood cancer patients become long-term survivors. Studies on the late effects of survivors are under way worldwide. However, data on Asian survivors remain limited.

Methods: Data on 241 survivors at the Long-term Follow-up Clinic in Severance Hospital, South Korea, were collected and late effects were confirmed by oncologists.

Results: The median follow-up from diagnosis was 7.8 years. Late effects were identified in 59.8% of survivors and 23.2% had two or more late effects. Grade 3 or higher late effects were present in 10.8%. The most common late effects involved endocrine system (29.0%). Late effects were present in 95.7% of brain tumor survivors and 36.0% of Wilms’ tumor survivors. Chemotherapy, hematopoietic stem-cell transplantation and radiotherapy were significant factors associated with the number and severity of late effects \( (P < 0.05) \). Brain tumor survivors had more severe late effects \( (P < 0.001) \), whereas Wilms’ tumor survivors had fewer and milder late effects \( (P < 0.05) \).

Conclusion: The observation that over 50% of cancer survivors suffered from late effects during the short follow-up period and that a high frequency of endocrine late effects was present indicates the need for early and well-timed intervention of the survivors.

Key words: cancer, childhood cancer, late effect, survivor

introduction

Recent advances in diagnosis, treatment and supportive care have greatly increased the childhood cancer survival rate to up to 80% [1]. As more survivors reach adulthood, chronic toxic effects in the survivors, the so-called ‘late effects’, are increasing in frequency [2, 3]. In the United States, ~1 of every 640 adults between the ages of 20 and 39 years is a childhood cancer survivor, and two of three of the survivors have at least one late effect [4].

The range of late effects is quite broad; growth, endocrine, cardiovascular, pulmonary, kidney and neurocognitive abnormalities have been reported [5, 6]. Due to increasing concern about the chronic health conditions and health status including quality of life (QoL) of survivors, many guidelines for long-term follow-up have been developed [7]. Many health professionals, including general physicians, oncologists, nurse practitioners and social workers, are working together to improve the health and QoL of the survivors [8, 9].

There are many published reports on late effects and health status, which includes general, mental and functional status [4, 10–13]. As for chronic adverse health conditions or late effects, most of the studies are on the single late effect of childhood cancer survivors and only a few reports are on their overall status of late effects. Furthermore, most prior reports investigated late effects in Caucasian populations. The purpose of this study was to assess the overall status of late effects of Asian childhood cancer survivors.

methods

patient selection

In January 2005, the Long-term Follow-up Clinic (LTFUC) for childhood cancer survivors was established at Severance Hospital, Yonsei University Health System (YUHS), Seoul, Korea. A childhood cancer survivor was defined as a person who survived for at least 2 years off of cancer therapy. There is a society of childhood cancer survivors at Severance Hospital comprising over 700 members including 408 survivors. We invited the survivors registered in this society by mail to come to the LTFUC. All patients were diagnosed at <18 years of age and were treated from 1980 to 2007 at Severance Hospital. Three hundred and fifty members visited the LTFUC from January 2005 to October 2007. We excluded the following members: those with a time after completion of treatment of <2 years
Among the members in the society, 408 were survivors and 241 survivor characteristics were tested by Student’s square test, and the significance for number and severity of late effects was analyzed. The existence of late effects, a complete history and physical examination was carried out for each survivor. The mean number of late effects over the lifespan of the survivors was 3.0 in the same way as in previous reports [4, 11]. The late effects were graded by the Common Terminology Criteria for Adverse Events version 3.0 in the same way as in previous reports [4, 11]. The late effects were scored from grades 1 to 5 with descriptions of severity for each adverse event (grade 1, mild; 2, moderate; 3, severe; 4, life threatening or disabling; 5, death-related adverse event). To compare the severity between risk groups and utilize the ordered meaning of grades, the grade was considered as a continuous variable from 1 to 5, based on other reports [17, 18]. In addition, the late effects were classified by organs and systems to avoid overlapping counts of late effects; the number of late effects represents the number of affected body systems (Table 1). The mean number of late effects per survivor, with specific risk factors, was calculated. The existence of late effects refers to whether a late effect existed or not.

**data analysis**

Late effects were defined as the adverse events that the survivors had at least 2 years after completion of therapy (Table 1). Specific late effects evaluated in the LTFUC were selected referring to the late effects stated in the aforementioned protocols [14–16]. The severity of specific late effect was graded by the Common Terminology Criteria for Adverse Events version 3.0 in the same way as in previous reports [4, 11]. The late effects were scored from grades 1 to 5 with descriptions of severity for each adverse event (grade 1, mild; 2, moderate; 3, severe; 4, life threatening or disabling; 5, death-related adverse event). To compare the severity between risk groups and utilize the ordered meaning of grades, the grade was considered as a continuous variable from 1 to 5, based on other reports [17, 18]. In addition, the late effects were classified by organs and systems to avoid overlapping counts of late effects; the number of late effects represents the number of affected body systems (Table 1). The mean number of late effects per survivor, with specific risk factors, was calculated. The existence of late effects refers to whether a late effect existed or not.

**statistical analyses**

The significance of various risk factors for the existence was tested by chi-square test, and the significance for number and severity of late effects was tested by Student’s t-test, one-way analysis of variance and correlation analysis using Pearson’s coefficient. The difference between two groups for nonparametric variables was tested by Mann–Whitney test. The risk factors that were significant in the univariate analyses were considered as the variables for multivariate analysis. Multiple linear regression for the association between risk factors and the number or severity of late effects and logistic regression to assess the odds ratio (OR) for the existence of late effects were carried out. Analyses were carried out using SPSS version 11.5.0 (SPSS System Inc., Chicago, IL).

**results**

**survivor characteristics**

Among the members in the society, 408 were survivors and 241 had responded (Table 2, supplemental Table S1, available at [Annals of Oncology](http://www.annonc.org) online). One hundred and fifty survivors were male (62.2%) and 91 were female (37.8%). The median age at diagnosis was 4.4 (0–16.8) years and the median current age was 14.2 (2.6–33.7) years. The median time elapsed after completion of treatment was 6.1 (2.0–21.6) years and the median time after diagnosis was 7.8 (2.0–23.1) years.

<table>
<thead>
<tr>
<th>Involved system</th>
<th>Specific late effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow</td>
<td>Anemia, polycythemia, leukopenia, marrow hypoproliferation, neutropenia, thrombocytopenia, thrombocytosis, other</td>
</tr>
<tr>
<td>Skin</td>
<td>Alopecia, atrophy, fibrosis, nail changes, vitiligo, other</td>
</tr>
<tr>
<td>Obesity</td>
<td>Obesity (based on BMI), other</td>
</tr>
<tr>
<td>Ear</td>
<td>Hearing loss, otitis externa, otitis media, tinnitus, other</td>
</tr>
<tr>
<td>Eye</td>
<td>Cataract, dry eye syndrome, glaucoma, retinopathy, uveitis, vitreous hemorrhage, other</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Cardiac arrhythmia, cardiomyopathy, congestive heart failure, hypertension, hypotension, ventricular dysfunction, other</td>
</tr>
<tr>
<td>Lung</td>
<td>Paranasal sinus infection, pneumonitis, pulmonary dysfunction, pulmonary fibrosis, other</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Bowel obstruction, colitis, dental abnormalities, chronic enterocolitis, constipation, fecal incontinence, hepatic dysfunction, ileus, malabsorption, mucositis, other</td>
</tr>
<tr>
<td>Kidney</td>
<td>Hematuria, hemorrhagic cystitis, incontinence, proteinuria, renal insufficiency, renal tubular disorder, other</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Ataxia, cerebrovascular ischemia, cognitive disturbance, dizziness, hydrocephalus, leukoencephalopathy, memory impairment, mood alteration, neuropathy (cranial, motor or sensory), phrenic nerve dysfunction, seizures, speech impairment, tremor, other</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Fracture, limb discrepancy, musculoskeletal hypoplasia, osteonecrosis, osteopenia, osteoporosis, scoliosis, other</td>
</tr>
<tr>
<td>Thyroid</td>
<td>Hyperthyroidism, hypothyroidism, thyroid nodule, other</td>
</tr>
<tr>
<td>Growth</td>
<td>Growth deceleration, growth hormone deficiency, short stature, other</td>
</tr>
<tr>
<td>Sexual/puberty</td>
<td>Delayed puberty, gonadotrophin secretion abnormality, gynecomastia, primary gonadal failure, premature menopause, infertility, irregular menses, precocious puberty, other</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Adrenal insufficiency, dyslipidemia, glucose intolerance, hypocalcemia, hypercalcemia, other</td>
</tr>
</tbody>
</table>

*Late effects were expressed using the terminology based on the Common Terminology Criteria for Adverse Events version 3.0. Adverse events confirmed 2 years after completion of cancer therapy were regarded as late effects rather than acute treatment toxic effects. Evaluation methods were selected based on risk and individualized follow-up schedules, which were determined according to the treatment history of the survivor. For all categories, history and physical examination were included. Evaluations were repeated at appropriate follow-up intervals for each late effect. BMI, body mass index.*
Table 2. Demographic characteristics of childhood cancer survivors at Severance Hospital

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. of survivors (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>150 (62.2)</td>
</tr>
<tr>
<td>Female</td>
<td>91 (37.8)</td>
</tr>
<tr>
<td>Age at diagnosis (median, range)</td>
<td>4.4 (0–16.8) years</td>
</tr>
<tr>
<td>Current age (median, range)</td>
<td>14.2 (2.6–33.7) years</td>
</tr>
<tr>
<td>Time elapsed after diagnosis (median, range)</td>
<td>7.8 (2.0–23.1) years</td>
</tr>
<tr>
<td>Time elapsed after completion of treatment (median, range)</td>
<td>6.1 (2.0–21.6) years</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>95 (39.4)</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>35 (14.5)</td>
</tr>
<tr>
<td>Wilms’ tumor</td>
<td>25 (10.4)</td>
</tr>
<tr>
<td>Brain tumor</td>
<td>23 (9.5)</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>13 (5.4)</td>
</tr>
<tr>
<td>Others</td>
<td>50 (20.7)</td>
</tr>
<tr>
<td>Treatment modalities</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy only with/without surgery</td>
<td>141 (58.5)</td>
</tr>
<tr>
<td>Radiotherapy only with/without surgery</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Chemotherapy and radiotherapy</td>
<td>92 (38.2)</td>
</tr>
<tr>
<td>Surgery only</td>
<td>7 (2.9)</td>
</tr>
<tr>
<td>Type of chemotherapy (n = 233, 96.7%)</td>
<td></td>
</tr>
<tr>
<td>Anthracyclines</td>
<td>124 (51.5)</td>
</tr>
<tr>
<td>Alkylating agents</td>
<td>152 (63.1)</td>
</tr>
<tr>
<td>Anthracyclines and alkylating agents</td>
<td>103 (42.7)</td>
</tr>
<tr>
<td>Others only</td>
<td>60 (24.9)</td>
</tr>
<tr>
<td>Type of radiotherapy (n = 93, 38.6%)</td>
<td></td>
</tr>
<tr>
<td>Head, neck and spine</td>
<td>65 (27.0)</td>
</tr>
<tr>
<td>Abdominopelvic</td>
<td>19 (7.9)</td>
</tr>
<tr>
<td>TBI</td>
<td>6 (2.5)</td>
</tr>
<tr>
<td>Chest</td>
<td>5 (2.1)</td>
</tr>
<tr>
<td>Type of surgery (n = 96, 39.8%)</td>
<td></td>
</tr>
<tr>
<td>Head</td>
<td>23 (9.5)</td>
</tr>
<tr>
<td>Abdominopelvic—kidney</td>
<td>27 (11.2)</td>
</tr>
<tr>
<td>Abdominopelvic—liver/adrenal gland</td>
<td>13 (5.4)</td>
</tr>
<tr>
<td>Chest</td>
<td>7 (2.9)</td>
</tr>
<tr>
<td>Type of HSCT (n = 42, 17.4%)</td>
<td></td>
</tr>
<tr>
<td>Autologous</td>
<td>20 (8.3)</td>
</tr>
<tr>
<td>Allogeneic</td>
<td>22 (9.1)</td>
</tr>
</tbody>
</table>

*Ninety-five survivors (39.4%) had leukemia and 35 (14.5%) had lymphoma. Other diagnoses included Wilms’ tumor (25, 10.4%), brain tumors (23, 9.5%), neuroblastoma (13, 5.4%) and others (50, 20.7%). Chemotherapy was given to 233 survivors (96.7%), radiotherapy to 93 (38.6%), surgery to 96 (39.8%) and hematopoietic stem-cell transplantation (HSCT) to 42 (17.4%). Chemotherapy and radiotherapy were given to 92 (38.2%) survivors simultaneously. Median dosage of anthracyclines in the group treated with anthracyclines was 167.9 (30.2–1160.0) mg/m².

Among 167 nonrespondents, 99 (59.3%) were male and 68 (40.7%) were female. The median age at diagnosis was 4.7 (0–17.1) years and it was not different from that of the respondents (P = 0.751). However, the median current age, age after completion of treatment and time after diagnosis in nonrespondents were significantly higher than those in the respondents (all P ≤ 0.001). As for the diagnosis, the proportion of brain tumor was significantly higher in nonrespondents than in respondents [n = 35 (21.0%) versus n = 23 (9.5%), P < 0.001; supplemental Table S1, available at Annals of Oncology online].

Overall late effects

Among the 241 survivors, 144 (59.8%) had at least one late effect and 97 (40.2%) had no late effects (Table 3). Two or more late effects were present in 60 survivors (24.9%). Sixty-one survivors (25.3%) had grade 1 (mild) late effects and 83 (34.4%) had grade 2 (moderate) or more severe late effects. Grade 3 or more late effects were found in 10.8% of survivors. There was no death (grade 5) in the LTFUC.

The most common late effects were endocrine related (Table 4). Among the survivors, 70 (29.0%) of 241 survivors had endocrine late effects including thyroid (n = 35), growth (n = 28), sexual (n = 28), metabolic (n = 5) and other abnormalities (n = 6). For grade 2 or higher, endocrine abnormalities were the most common late effects that required treatment (30, 12.4%). Among these cases, 16 had growth abnormalities and 10 had sexual/pubertal abnormalities. For grade 3 or higher, neurologic (n = 7) and endocrine (n = 7) abnormalities were the most common.

Three relapses occurred: a neuroblastoma patient relapsed 2.2 years after completion of therapy, a patient with medulloblastoma relapsed at 2.3 years and a patient with acute lymphoblastic leukemia relapsed at 3.8 years.

Three patients who were enrolled in the LTFUC at first are now in the HOC due to secondary malignancy: a patient diagnosed with glioblastoma multiforme at 8.5 years of age and then developed undifferentiated sarcoma in the bladder at 15.1 years of age, a patient with medulloblastoma at 14.2 years of age, and then developed acute myeloid leukemia at 19.9 years of age and a patient with neuroblastoma at 1.0 year of age and then developed brain germinoma at 5.5 years of age. Patients with second malignancies are treated and followed in the HOC and were not included in the analysis of late effects in the 241 survivors.

Late effects and treatment

Number of late effects. There was no gender difference in the number of late effects among the survivors (Table 5). Brain
tumor survivors had the highest probability of having late effects (95.7%, 22 of 23). Wilms’ tumor survivors had the lowest risk for late effects (36.0%, 9 of 25). In terms of multiple late effects, 52.2% of brain tumor survivors (12 of 23) had two or more late effects. Only one Wilms’ tumor (4.0%, 1 of 25) and two neuroblastoma survivors (15.3%, 2 of 13) had multiple late effects. A history of a brain tumor was a significant risk factor for an increased number of late effects (1.83 ± 0.22; \( P < 0.001 \)) compared with a history of other childhood cancers. Wilms’ tumor survivors were at lower risk for late effects compared with other cancer survivors (0.44 ± 0.14; \( P < 0.001 \)).

Chemotherapy, HSCT and radiotherapy were significant risk factors for a high number of late effects (all \( P < 0.001 \)) when compared with survivors not treated with each of these modalities. The age at diagnosis and the current age correlated positively to the number of late effects (\( r = 0.25, P < 0.001 \); \( r = 0.13, P = 0.049 \)). Multivariate analysis showed that all treatment modalities were related to an increased mean number of late effects. Wilms’ tumor survivors had a decreased number of late effects (Table 6).

### overall grade of severity of late effects
Survivors treated with radiotherapy had a much higher grade of late effects than did survivors who did not receive radiotherapy (1.5 ± 0.1 versus 0.8 ± 0.1, \( P < 0.001 \)) (Figure 1). A history of chemotherapy or HSCT was associated with more severe late effects when compared with the grade of late effects in survivors who did not receive chemotherapy or HSCT (1.1 ± 0.1 versus 0.1 ± 0.1, \( P < 0.001 \); 1.4 ± 0.1 versus 1.0 ± 0.1, \( P = 0.025 \)). These findings were confirmed by the multivariate analysis controlling for other factors such as gender, age at diagnosis and current age (all \( P < 0.05 \), Table 6).

Regarding diagnosis, 52.2% of all brain tumor survivors (12 of 23) had grade 3 or higher late effects, compared with only 4.2% of leukemia survivors (4 of 95). The mean grade of late effects in brain tumor survivors was much higher than that for survivors who did not have a brain tumor (2.3 ± 0.2 versus 0.9 ± 0.1, \( P < 0.001 \)) (Figure 1). The severity of late effects in Wilms’ tumor survivors was milder than in the survivors who did not have Wilms’ tumor (0.6 ± 0.2 versus 1.1 ± 0.1, \( P < 0.012 \)). The effects associated with a history of brain tumors and Wilms’ tumors were confirmed by the multivariate analysis (Table 6). The mean age at diagnosis correlated positively with the severity grade of late effects (\( r = 0.180, P = 0.001 \)); however, the current age and the time elapsed after treatment did not.

### relationship between severity grade of specific late effects and treatment
Among the treatment modalities, chemotherapy was associated with an increased growth and obesity severity grade compared with the survivors who did not receive chemotherapy (0.22 ± 0.04 versus 0, \( P < 0.001 \); 0.27 ± 0.05 versus 0, \( P < 0.001 \)) (Figure 1). Radiotherapy increased the severity of growth, thyroid and sexual late effects (0.36 ± 0.08 versus 0.11 ± 0.04, \( P = 0.006 \); 0.50 ± 0.08 versus 0.15 ± 0.05, \( P = 0.001 \); 0.51 ± 0.11 versus 0.14 ± 0.06, \( P = 0.003 \)). However, all the effects associated with a history of radiotherapy were not confirmed by the multivariate analysis after controlling for age, gender, diagnosis and other treatment modalities. A history of surgery increased the severity of growth, thyroid and kidney late effects compared with the survivors who did not have surgery by the univariate analysis (0.42 ± 0.08 versus 0.08 ± 0.03, \( P = 0.001 \); 0.56 ± 0.11 versus 0.24 ± 0.05, \( P = 0.013 \); 0.22 ± 0.07 versus 0.05 ± 0.02, \( P = 0.023 \)). The effects of surgery on growth and kidney abnormalities were confirmed by the multivariate analysis (\( P < 0.05 \)).
A brain tumor was associated with higher odds for the existence of late effects (OR 22.8, 95% confidence interval (CI) 1.5–358.3; OR 3.9, 95% CI 1.5–9.9; OR 2.2, 95% CI 1.1–4.5) compared with the survivors who did not undergo treatment, chemotherapy, HSCT and radiotherapy all increased the odds for having late effects (OR 22.8, 95% CI 1.5–358.3; OR 3.9, 95% CI 1.5–9.9; OR 2.2, 95% CI 1.1–4.5) compared with the survivors who did not undergo each of the treatment modalities (Table 7). The diagnosis of a brain tumor was associated with higher odds for the existence of late effects (OR 16.6; 95% CI 1.4–192.8) compared with the leukemia survivors. Wilms’ tumor survivors had a tendency for lower risk of late effects than leukemia survivors (OR 0.3; 95% CI 0.1–1.2; P = 0.097).

**Discussion**

To recognize the prevalence and severity of late effects and to provide timely intervention are the mainstay of health care for the childhood cancer survivors. Our findings showed that 59.8% of survivors had late effects and 34.4% had grade 2 or more severe late effects that required treatment. Although the overall findings for the late effects were similar to those previously reported, there were some differences.

According to the studies in the United States [4] and The Netherlands [11], 62.3% and 74.5%, respectively, of childhood cancer survivors had adverse health conditions. In the UK [19], 58% of survivors had chronic medical problems. The prevalence of late effects in our report was slightly lower than...
the values reported in recent studies in the United States and The Netherlands. The main difference in the studies is likely due to the length of follow-up. In our study, the median time elapsed after completion of treatment was 6.1 years, and the median time after diagnosis was 7.8. However, all three prior studies had a follow-up period of over 15 years from diagnosis. The difference might also be due to the treatment intensity. The study population in this study is one of the most recent cohorts. Recent treatments are now focusing on reducing toxicity while achieving comparable survival rates in order to minimize adverse health conditions [20]. Nevertheless, the fact that nearly 60% of survivors had late effects, even within our short study period and even with less toxic treatments, raises concern that the survivors require regular follow-up and early intervention for late effects.

As for the severity of late effects, 27.5% of survivors in the United States and 40.0% in The Netherlands suffered from grade 3 or higher late effects. Only 10.8% of survivors had grade 3 or higher late effects in our study. The differences are likely due to the diagnoses included and the relatively short follow-up interval. According to other studies, brain and bone tumors, in addition to radiotherapy, are higher risk factors for late effects [11, 13]. In the USA study, 10.9% of patients had bone tumors and 12.7% of cases were central nervous system (CNS) tumor survivors. In The Netherlands study, 8.5% had bone tumors and 7.9% had CNS tumors. In our study, the proportion of brain tumor survivors was similar (9.5%), but there were no bone tumor survivors. Furthermore, survivors treated with radiotherapy (38.6%) were fewer than in other studies (62.2% [4], 44.6% [11]).

The number of late effects in this study represents the extent of affected body systems. The brain tumor survivors had the highest number of late effects among the diagnoses evaluated. Survivors with radiotherapy or HSCT had an increased number of late effects per survivor compared with survivors who did not undergo radiotherapy or HSCT. These findings suggest that these factors are associated with a greater effect on body systems compared with other factors and are consistent with other reports [4, 11, 21, 22]. The risk factors associated with brain tumors lost their significant association with the number of late effects in the multivariate analysis, which controlled for the treatment modalities (Table 6). This implies that radiotherapy and surgery were more important risk factors than the brain tumor itself for the extent of late effects.

Radiotherapy was a significant risk factor for the overall prevalence and severity of late effects, consistent with the findings of many other reports [6, 23–26]. When we evaluated the effects of radiotherapy on individual late effects such as growth, sexual and thyroid abnormalities, radiotherapy showed a clear tendency of more severe late effects; however, this tendency was not confirmed by the multivariate analysis, perhaps due to the limited number of cases.
be because Wilms’ tumor has the best prognosis among childhood cancers; it requires less intensive therapies compared with other tumors and survivors can live without problems with only one kidney. Therefore, Wilms’ tumor survivors seem to have a higher QoL to some extent compared with other tumor survivors although childhood cancer survivors generally have almost the same QoL as the general population [32, 33].

The evaluation of age points to a higher risk of late effects among adolescent survivors [23]. As the survivors grow older and enter puberty, late effects become more evident in terms of growth and pubertal development. However, the results of this study showed no consistent findings associated with the age at diagnosis or the current age with regard to the late effects. This might be due to the relatively short follow-up and the fact that many of the survivors evaluated had not entered puberty yet.

The age issue could also be related with the absence of bone tumor survivors in this study. Bone tumors are observed most frequently in adolescents [34]. Bone tumor survivors have more late effects and suffer from more severe functional impairments [35]. Moreover, second malignancies occur more frequently than other tumor survivors [36]. Musculoskeletal late effects including limb abnormalities might impair growth in adolescents, and late effects would have been more evident in the adolescent age if bone tumor survivors had been included in this study. Because of these reasons, prevalence and severity of late effects and frequency of second malignancy could have been less than in other reports.

The nonrespondents (n = 167) in this study might distort the results of this study. Because they have higher current age, age after completion of treatment and longer time after diagnosis, and a much higher proportion of having brain tumors than in respondents, the frequency and severity of late effects might have been higher and more severe if the nonrespondents had participated in the LTFUC.

The CIs of the OR for the existence of late effects in brain tumor survivors or survivors with chemotherapy were wide. These findings were due to the characteristics of the study subjects; almost all cancer survivors (96.7%) had chemotherapy, and almost all brain tumor survivors (95.7%) had late effects. However, it is still evident that these two factors increased the OR.

The limitations of this study included the small study population size and the short follow-up duration compared with previous studies. It is possible that the prevalence of late effects was underestimated. This could be addressed by continued follow-up of the enrolled survivors. Another limitation was the absence of bone tumor survivors.

This study has some unique points. This is the first report on late effects of childhood cancer survivors in the Asian–Pacific region. Differences in pharmacokinetics and pharmacodynamics according to the ethnicity cause differences in efficacy and side-effects [37]. Sociocultural background might influence health behaviors to seek medical care such as screening tests [38]. These factors could be related with the incidence and severity of late effects and the participation rate in the LTFUC. Secondly, we evaluated the overall health status of childhood cancer survivors, not only focusing on late effects on a single-body system.

Thirdly, all survivors were examined by oncologists and assessed with laboratory and radiological tests.

---

**Table 7. Multivariate analysis of the effect of risk factors on the existence of late effects**

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Existence of late effects</th>
<th>OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td>0.9 (0.5–1.6)</td>
<td>0.631</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td></td>
<td>1.0 (0.9–1.1)</td>
<td>0.893</td>
</tr>
<tr>
<td>Current age</td>
<td></td>
<td>1.0 (0.9–1.1)</td>
<td>0.878</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>22.8 (1.5–358.3)</td>
<td>0.026</td>
</tr>
<tr>
<td>HSCT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>3.9 (1.5–9.9)</td>
<td>0.004</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>2.2 (1.1–4.5)</td>
<td>0.023</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>1.2 (0.3–3.1)</td>
<td>0.636</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Lymphoma</td>
<td></td>
<td>0.8 (0.3–2.0)</td>
<td>0.597</td>
</tr>
<tr>
<td>Brain tumor</td>
<td></td>
<td>16.6 (1.4–192.8)</td>
<td>0.025</td>
</tr>
<tr>
<td>Wilms’ tumor</td>
<td></td>
<td>0.3 (0.1–1.2)</td>
<td>0.097</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td></td>
<td>1.4 (0.2–8.4)</td>
<td>0.716</td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td>1.2 (0.5–3.0)</td>
<td>0.762</td>
</tr>
</tbody>
</table>

All factors used in the model are presented in the table.
OR, odds ratio; CI, confidence interval; HSCT, hematopoietic stem-cell transplantation.

Surgery, including brain surgery and nephrectomy, was found to be associated with an increase in the severity of endocrine and kidney abnormalities. Brain surgery is usually linked with brain tumors and radiotherapy; in such cases, the risk of having endocrine abnormalities is higher. The effect of surgery on kidney abnormalities might be due to nephrectomies for Wilms’ tumor and neuroblastoma. These tumors are linked with the use of kidney-toxic agents like platinum-based drugs [27]; all these factors influence the effect of a nephrectomy on the severity of late effects.

There have been many reports documenting endocrine, especially thyroid, abnormalities in childhood cancer survivors [4, 11, 22, 23, 28, 29]. Our findings were consistent with prior reports. Endocrine late effects are common and important problems at the LTFUC. First, they adversely affect the QoL because of the interference with normal growth and development and psychological adjustment [26, 30, 31]. Secondly, endocrine abnormalities are the most common late effects. Thirdly, such problems can be appropriately managed by timely intervention during child development [30], which further emphasizes the important role of the LTFUC.

In contrast to other factors, Wilms’ tumor survivors had fewer and less severe late effects than the other survivors. This finding is consistent with previous studies [4, 12]. This might
In conclusion, the results of this study showed that late effects were common in survivors and were apparent during a short interval of follow-up after diagnosis. The most common late effects were associated with the endocrine system. Endocrine abnormalities can be managed by meticulous and well-timed hormone replacement therapy. These findings suggest that late effects of childhood cancer survivors must be continuously monitored after the completion of cancer treatment, so that timely and effective treatment can be initiated.

funding


acknowledgements

We would like to thank one of our colleagues Sun-Young Ahn for the invaluable time and expertise she provided during the preparation of the revised manuscripts. We also thank Sun Young Son for her efforts in helping to establish the Long-term Follow-up Clinic in Severance Hospital, Yonsei University Health System, Seoul, Korea.